| abstract |
The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening By segregating anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies such as the monoclonal antibody produced by the hybridoma deposited with the ATCC as accession no PTA-5643. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumours, e g breast or ovarian tumour metastases The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells. |